Sorry, mate. Only reading this now.
Yes it does, and most likely the same company it's doing its comparator study against. Read up on Axogen Inc. and specifically Axoguard. They also have their Avance Nerve Graft product (an allograft product), but this still requires the use of their Axoguard (plus sutures) to encompass both ends of the Avance graft attachement.
Their allograft product’s success rate shows a whopping 52.6% – 86% differential between recovery rates. Better than nothing, but hardly spectacular.
Media thread, page-550
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $65.71K | 166.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1052 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 354895 | 8 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |